Clinical trials: Obese Subjects
Obesity
A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age
Study will evaluate the pharmacokinetics (PK), safety and tolerability of a single 10 mg dose of lorcaserin hydrochloride in obese pediatric subjects 6 to 11 years of age.
- Trial name
- NCT02398669
- Testing
- Lorcaserin hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eisai Inc.
Overweight and Obesity
Evaluation of Obex® in Overweight and Obesity
Obesity is an important and growing worldwide Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer Diverse adverse events have been reported with the use of antiobesity…
- Trial name
- NCT03541005
- Testing
- Obex
- Where
- Cuba
- Volunteers
- 160 people
- Sponsor
- Catalysis SL
Overweight and Obesity
The Food Effect on Pharmacokinetics of DA-302168S
This study will be conducted to determine the effect of food on the pharmacokinetics characteristic of DA-302168S following administration of a DA-302168S tablet with and without a high-fat meal.
- Trial name
- DA168 (NCT06534346)
- Testing
- 15 mg DA-302168S tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Adverse Drug Event, Side Effects of Drugs
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.
- Trial name
- NCT03112083
- Testing
- Nutritional counseling A, Nutritional counselling B
- Where
- Finland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Olympic Seafood AS
Overweight, Obesity
Benefit and Tolerability of IQP-AE-103 in Weight Loss
This study is to evaluate the benefit and tolerability of two dosages of IQP-AE-103 (990mg and 1980mg daily) in reducing body weight in overweight and moderately obese subjects
- Trial name
- NCT03058367
- Testing
- IQP-AE-103 (330mg), IQP-AE-103 (165mg)
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Overweight and Obesity
Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects
Glucosanol™, the medical device to be investigated contains a proprietary plant extract that is a natural inhibitor of alpha-amylase and can reduce starch digestion.
- Trial name
- NCT01407393
- Testing
- Glucosanol
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity & Overweight
A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.
- Trial name
- NCT07570758
- Testing
- ERX1000
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- ERX Pharmaceuticals
Overweight and Obesity
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.
- Trial name
- NCT06532578
- Where
- Australia
- Volunteers
- 240 people
- Sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
Obesity, Overweight
A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects
This study is an open-label, fixed-sequence, self-controlled Phase I clinical trial conducted among obese or overweight subjects, with a planned enrollment of 40 adult subjects.
- Trial name
- NCT07269756
- Testing
- HRS-7535 Tablets, Paracetamol Tablets, Digoxin Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program…
- Trial name
- NCT00456521
- Testing
- Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Intensive group lifestyle modification counseling
- Where
- 9 sites in United States
- Volunteers
- 793 people
- Sponsor
- Orexigen Therapeutics, Inc
Nonalcoholic Fatty Liver Disease
A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending subcutaneous (SC) doses of CB4211 in…
- Trial name
- NCT03998514
- Testing
- CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- CohBar, Inc.
Obesity
Feasibility Trial of ValenTx Endo Bypass System of the ValenTx Endo Bypass System in Obese Subjects
The purpose of this study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese subjects
- Trial name
- NCT01207830
- Testing
- Endo Bypass System
- Where
- Mexico
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- ValenTx, Inc.
Diabetes
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
- Trial name
- NCT04973111
- Testing
- CT-868 as SC Injection, Active Comparator as SC Injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Obesity or Overweight
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of GZR18 Injection on gastric emptying and the effect of repeated SC injections of GZR18 Injection on the pharmacokinetics of oral…
- Trial name
- NCT07128888
- Testing
- GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Overweight, Obesity
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
The purpose of this study is to determine how VI-0521 affect speed and reaction time on specific tasks that require eye and hand coordination, compared to placebo.
- Trial name
- NCT00806260
- Testing
- VI-0521, Alcohol
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Overweight and Obesity
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects
- Trial name
- NCT06714825
- Testing
- HS235
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- 35Pharma Inc., a GSK company
Abdominal Obesity
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
Dose-ranging, randomized, double-blind, vehicle-controlled study
- Trial name
- NCT05422378
- Testing
- STP705
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sirnaomics
Metabolism and Nutrition Disorder, Obesity
Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity
This study looks at a new study medicine for weight management in people with overweight or obesity. The aim of this study is to find out how safe and tolerable the study medicine is.
- Trial name
- NCT03308721
- Testing
- NNC9204-1177 A 1.0 mg/mL
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of DA-302168S tablets in overweight and obese adults.
- Trial name
- DA168 (NCT06953063)
- Testing
- DA-302168S
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Hypothalamic Obesity, Prader-Willi Syndrome
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment
- Conditions
- Hypothalamic Obesity, Prader-Willi Syndrome, PWS
- Trial name
- NCT06239116
- Testing
- Part C: RM-718, Part D: RM-718
- Where
- 7 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Rhythm Pharmaceuticals, Inc.